WYOST

This brand name is authorized in United States. It is also authorized in Canada, Lithuania.

Active ingredients

The drug WYOST contains one active pharmaceutical ingredient (API):

1	Denosumab UNII 4EQZ6YO2HI - DENOSUMAB
	Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing activation of its receptor, RANK, on the surface of osteoclast precursors and osteoclasts. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone.
	Read more about Denosumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
WYOST Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
WYOST Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M05BX04	Denosumab	M Musculo-skeletal system → M05 Drugs for treatment of bone diseases → M05B Drugs affecting bone structure and mineralization → M05BX Other drugs affecting bone structure and mineralization
Discover more medicines within M05BX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02545764
LT	Valstybinė vaistų kontrolės tarnyba	1099872
US	FDA, National Drug Code	61314-228